| Diabetes Mellitus
Novolog vs Toujeo
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus.Deep comparison between: Insulin Diluting Medium For Novolog vs Toujeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsToujeo has a higher rate of injection site reactions vs Insulin Diluting Medium For Novolog based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Toujeo but not Insulin Diluting Medium For Novolog, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Insulin Diluting Medium For Novolog
Toujeo
At A Glance
SC injection
Pre-meal
Rapid-acting insulin analog
SC injection
Once daily
Long-acting insulin analog
Indications
- Diabetes Mellitus
- Diabetes Mellitus
Dosing
Diabetes Mellitus Inject SC within 5-10 minutes before a meal into the abdominal area, thigh, buttocks, or upper arm; generally used with an intermediate- or long-acting insulin; may also be administered via continuous SC infusion pump or diluted to 0.05-1 unit/mL for IV infusion; individualize dose based on metabolic needs and blood glucose monitoring results.
Diabetes Mellitus, Type 1 (insulin-naive) Approximately one-third to one-half of total daily insulin dose SC once daily; remainder given as short-acting insulin divided between daily meals.
Diabetes Mellitus, Type 2 (insulin-naive) 0.2 units/kg SC once daily.
Switching from once-daily long/intermediate-acting insulin Start at same unit dose as prior once-daily long-acting insulin SC once daily; monitor glucose closely during initial weeks.
Switching from twice-daily long/intermediate-acting insulin Start at 80% of total daily NPH or insulin detemir twice-daily dosage SC once daily; monitor glucose frequently.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to NOVOLOG or one of its excipients
- Active hypoglycemia episode
- Hypersensitivity to insulin glargine or any excipient in Toujeo
Adverse Reactions
Most common (>=5%) Headache, accidental injury, nausea, diarrhea (type 1 diabetes); hyporeflexia, onychomycosis, sensory disturbance, urinary tract infection, chest pain, skin disorder, abdominal pain, sinusitis (type 2 diabetes)
Serious Severe hypoglycemia, generalized allergy/anaphylaxis, hypokalemia, lipodystrophy, peripheral edema
Postmarketing Localized cutaneous amyloidosis at injection site, medication errors with insulin substitution, hyperglycemia or hypoglycemia associated with amyloidosis-related injection site changes
Most common (>=5%) nasopharyngitis, upper respiratory tract infection, hypoglycemia
Serious severe hypoglycemia, anaphylaxis, peripheral edema, lipodystrophy, hypokalemia
Postmarketing localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injections into or away from amyloidosis areas
Pharmacology
Rapid-acting human insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose production, with peak glucose-lowering effect 1-3 hours after SC injection and duration of action 3-5 hours.
Long-acting insulin analog; regulates glucose metabolism by stimulating peripheral glucose uptake in skeletal muscle and fat, inhibiting hepatic glucose production, inhibiting lipolysis and proteolysis, and enhancing protein synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Insulin Diluting Medium For Novolog
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
Toujeo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Insulin Diluting Medium For Novolog
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Toujeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Insulin Diluting Medium For Novolog
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Toujeo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Insulin Diluting Medium For Novolog.
No savings programs available for Toujeo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Insulin Diluting Medium For NovologView full Insulin Diluting Medium For Novolog profile
ToujeoView full Toujeo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.